Initial Statement of Beneficial Ownership (3)
03 Juin 2021 - 11:31PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
VEDANTA PARTNERS, LLC |
2. Date of Event Requiring Statement (MM/DD/YYYY)
6/1/2021
|
3. Issuer Name and Ticker or Trading Symbol
REVIVA PHARMACEUTICALS HOLDINGS, INC. [RVPH]
|
(Last)
(First)
(Middle)
C/O VEDANTA MANAGEMENT LP, 250 WEST 55TH STREET, SUITE 13D |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
NEW YORK, NY 10019
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 99539 | I | See Footnote (1) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Held directly by Vedanta Associates, L.P. ("Vedanta Associates"). Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported herein, except to the extent of any pecuniary interest therein. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
VEDANTA PARTNERS, LLC C/O VEDANTA MANAGEMENT LP 250 WEST 55TH STREET, SUITE 13D NEW YORK, NY 10019 |
| X |
|
|
Vedanta Associates-R, LP C/O VEDANTA MANAGEMENT LP 250 WEST 55TH STREET, SUITE 13D NEW YORK, NY 10019 |
| X |
|
|
VEDANTA ASSOCIATES, L.P. C/O VEDANTA MANAGEMENT LP 250 WEST 55TH STREET, SUITE 13D NEW YORK, NY 10019 |
| X |
|
|
BETA OPERATORS FUND, L.P. C/O VEDANTA MANAGEMENT LP 250 WEST 55TH STREET, SUITE 13D NEW YORK, NY 10019 |
| X |
|
|
Signatures
|
/s/ Parag Saxena - for Vedanta Partners, LLC, by Parag Saxena, its CEO | | 6/3/2021 |
**Signature of Reporting Person | Date |
/s/ Parag Saxena - for Vedanta Associates-R, LP, by Vedanta Partners, LLC, its general partner, by Parag Saxena, its CEO | | 6/3/2021 |
**Signature of Reporting Person | Date |
/s/ Parag Saxena - for Vedanta Associates, LP, by Vedanta Partners, LLC, its general partner, by Parag Saxena, its CEO | | 6/3/2021 |
**Signature of Reporting Person | Date |
/s/ Parag Saxena - for Beta Operators Fund, L.P., by Vedanta Associates, LP, its general partner, by Vedanta Partners, LLC, its general partner, by Parag Saxena, its CEO | | 6/3/2021 |
**Signature of Reporting Person | Date |
Reviva Pharmaceuticals (NASDAQ:RVPH)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Reviva Pharmaceuticals (NASDAQ:RVPH)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025